Home
NewsNewsLatest development marks a transformative step in endometriosis care by reducing diagnostic delays and enabling earlier treatment for improved patient outcomes. ENDOSURE's rapid and accurate diagnostic capability is expected to benefit thousands of women suffering from this chronic condition across Canada.
EndoDiagnosis has announced that CReATe Fertility is the first clinic in Canada to offer the innovative Tier 1 ENDOSURE diagnostic test for endometriosis, authorized by Health Canada since 2021. This non-invasive diagnostic test provides an accurate and rapid alternative to the traditional gold standard of laparoscopic surgery for diagnosing endometriosis, a chronic and often debilitating inflammatory disease affecting women globally.
The ENDOSURE test offers 99% accuracy, delivering results within 30 minutes during a single clinic visit without the need for referrals or laboratory processing. It detects all types and stages of endometriosis and is suitable for women of all ages, from pre-teens to post-menopausal individuals. This enables healthcare providers to quickly confirm endometriosis as the cause of menstrual or abdominal pain and infertility, which are common symptoms of the disease.
Endometriosis affects at least 10% of women worldwide, yet diagnosis is often delayed by 3 to 11 years due to the limitations and invasiveness of laparoscopy. Many patients endure prolonged suffering without accurate diagnosis because symptoms overlap with other conditions, and pain is sometimes dismissed by clinicians or attributed to normal menstrual discomfort. Tier 1 diagnostic testing like ENDOSURE addresses this diagnostic gap by providing a reliable, pain-free, and fast diagnostic option.
By incorporating ENDOSURE, CReATe Fertility is leading the way in Canadian reproductive healthcare to accelerate diagnosis and treatment. Early identification of endometriosis is critical as it allows for timely symptom management and interventions that can slow or stop disease progression and improve fertility outcomes. The ability to diagnose in real time also helps clinicians monitor patient responses post-treatment and adjust care plans accordingly.
The offering of the Tier 1 ENDOSURE test at CReATe Fertility empowers both patients and healthcare providers with a decision-support tool that transforms the experience of care. Patients gain faster access to answers, reducing years of uncertainty and enabling better quality of life. Clinicians receive actionable diagnostic data to guide personalized treatment pathways without the risks or costs associated with surgery.
This move is part of EndoDiagnosis’ broader mission to revolutionize endometriosis care worldwide by making rapid, accurate, and non-invasive diagnostics accessible. The company supports providers with education and a network to facilitate the adoption of ENDOSURE. With the introduction of this test in Canada, women suffering from chronic pelvic pain and infertility symptoms now have access to state-of-the-art diagnostics that validate their experiences and offer hope for better management.
The Stork Foundation for Infertility received a record 1,076 grant applications in 2026, with data revealing that 85% of applicants have no fertility treatment coverage for the care they are pursuing. Average anticipated next treatment costs stand at 19,149 USD, with 39% having already spent more than 10,000 USD out of pocket.
Future Health, A Global Initiative by Abu Dhabi has launched the Future Health Digital Health Innovation Challenge 2026, inviting global innovators to develop AI, software, and connected technology solutions across fertility, population health, and well-being. Three finalists will share USD 105,000 at GITEX 2026, with selected solutions eligible for incubation and scale.
La Trobe University and GonGlobal have entered a strategic collaboration to develop and validate AI and digital twin technologies for ART and IVF. The partnership will build AI-driven fertility care tools, including cohort matching digital twins and deep-learning models, to predict pregnancy outcomes and support personalised clinical decision-making.
IVI Institute has announced the acquisition of The World Egg and Sperm Bank (TWESB), founded in 2004 and operating from Scottsdale, Arizona. The move expands access to reproductive solutions for patients and clinics across the United States and Australia, combining TWESB’s network of 500+ screened donors with IVI Institute’s global clinical and scientific infrastructure.
Doctors at NHS Lothian in Edinburgh have performed the UK’s first testicular tissue transplant, reimplanting tissue frozen before chemotherapy in a 19-year-old patient with a serious blood disorder. The testicular tissue transplant, only the second reported worldwide, could eventually give thousands of young boys a realistic path to future fatherhood.
Flora Fertility and Clue have announced the Flora Clue fertility partnership, connecting the first individually owned fertility insurance platform with the world’s leading women-led cycle tracking app. FLORA policyholders receive complimentary Clue Plus access, while Clue’s community of over 100 million members gains early exposure to proactive fertility financial planning.
The World Health Organization releases its first comprehensive, evidence-based global guideline for infertility prevention, diagnosis, and treatment. Addressing one in six people of reproductive age worldwide, the guideline emphasizes equity, human rights, and standardized interventions to improve access to fertility care globally.
